IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 14913 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  
Resource Links
 »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »  Article in PDF (380 KB)
 »  Citation Manager
 »  Access Statistics
 »  Reader Comments
 »  Email Alert *
 »  Add to My List *
* Registration required (free)

 
In This Article
 »  References
 »  Article Figures

 Article Access Statistics
    Viewed2489    
    Printed160    
    Emailed0    
    PDF Downloaded111    
    Comments [Add]    

Recommend this journal

 


 
 Table of Contents    
LETTER TO THE EDITOR
Year : 2016  |  Volume : 48  |  Issue : 1  |  Page : 99-100
 

Cytotoxic activity of a glaucoside from Eugenia jambolana against MCF-7 cells


Department of Biotechnology, Bishop Heber College, Tiruchirappalli, Tamil Nadu, India

Date of Web Publication20-Jan-2016

Correspondence Address:
R Jasmine
Department of Biotechnology, Bishop Heber College, Tiruchirappalli, Tamil Nadu
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.174587

Rights and Permissions



How to cite this article:
Jasmine R, Kumar S A. Cytotoxic activity of a glaucoside from Eugenia jambolana against MCF-7 cells. Indian J Pharmacol 2016;48:99-100

How to cite this URL:
Jasmine R, Kumar S A. Cytotoxic activity of a glaucoside from Eugenia jambolana against MCF-7 cells. Indian J Pharmacol [serial online] 2016 [cited 2023 Sep 24];48:99-100. Available from: https://www.ijp-online.com/text.asp?2016/48/1/99/174587


Sir,

Breast cancer, as a chronic disease, is a commonly identified cancer in female in both economically developed and developing countries. [1] There are various treatments approaches that have been aimed toward treatment of this disease, but the success rate of the chemotherapeutic drugs are reported to be low; with high rate of recurrence and various side effects. Natural compounds or dietary agents have been used as an important tool to treat cancer because of its low cytotoxicity and less adverse effects. Breast cancer can metastasize to lymph nodes and distant organs from the primary site which is usually the cause of death. Plants and natural products play an important role in medicine and provide important prototypes for the development of novel drugs. [2] They offer a valuable source of compounds with a wide variety of biological activities and chemical structures. Many anticancer agents have been derived from natural sources; directly as pure native compounds, or as semi-synthetic analogs. [3],[4],[5] Since the dawn of civilization, herbal drugs have been used in the ancient civilizations and their use in the treatment of cancer is on a rise, especially in the developing and underdeveloped countries primarily due to its easy affordability, nontoxic nature, easy acceptability, less toxic or no toxic effects, and easy availability. Among the several plants reported to possess anticancer activity, Eugenia jambolana is one among the many plants, which has not been investigated for anticancer activity. The present study proves the traditional claims of the plant against cancer. [6] The berries have been reported to possess activity against breast cancer. [7] This paper will possibly help to bridge between traditional claims and modern therapy on E. jambolana. This paper reports the isolation, structure determination and biological activities of a steroidal saponin, glaucoside J. Spectral data led to the structure of the compound as 5,6-dihydroxy-3- [(4-hydroxy-6-(hydroxymethyl) -3,5-di [3, 4, 5-trihydroxy-6-(hydroxymethyl) tetrahydro-2H-2-pyranyl] oxytetrahydro-2H-2-pyranyl) oxy]-2-methoxy-10, 13-dimethylperhydro cyclopenta[α]phenanthren-17-yl (phenyl) methylacetate from E. jambolana seeds.

Saponins are natural glycosides which possess a wide range of pharmacological properties.

The MTT assay was performed according to the method set out by Mosmann. Jambosine, gallic acid, ellagic acid, corilagin, 3,6- hexahydroxydiphenoylglucose, 1-galloylglucose, 3-galloylglucose, quercetin, β -sitosterol, and 4,6 hexahydroxydiphenoylglucose are a few bioactive compounds isolated and identified from E. jambolana. In this work, glaucoside (compound) isolated from E. jambolana not only inhibited cancer cell proliferation but also in addition induced cancer cell apoptosis. The isolated new saponin, glaucoside, was found to demonstrate remarkable apoptotic property on MCF-7 cells. The effect was also found to be concentration dependent.

The compound was tested against MCF-7 cell lines at five different concentrations as 300, 150, 75.37.5, and 18.75 μg/mL for 24 h [Figure 1]. The antiproliferative bioassay showed that both the extract and compound inhibited the growth of the MCF-7 breast cancer cells in both dose- and time-dependent manner. The concentrations required to inhibit the growth of 50% of the cells, i.e., IC50 values were calculated for both the samples against MCF-7 cell lines. The IC50 values were 253.6 μg/mL for the methanol extract and 176.2 μg/mL for the compound. It is noteworthy that the crude methanol extract was less effective at reducing the proliferation of the MCF-7 cells when compared to the compound. Nevertheless, our results provide preliminary data as to the ability of the extract and compound to inhibit the growth and induce apoptosis of human breast cancer cell lines in vitro. The results of this study warrant further investigation into the potential of E. jambolana berries and its derived food products, as chemopreventive agents against breast cancer. In addition, our future studies will investigate the possible mechanism of action against the proliferation and survival of breast cancer cell lines. This compound may provide clues for designing a range of novel semi-synthetic and synthetic compounds as medicinal anticancer agents in the near future. Further studies on the mode of action and the role of compound on pro-apoptotic factors are under progress. This report is the first of its kind to report the anticancer activity of the new glaucoside isolated. In conclusion, the plant and its compound examined in this study possess varying levels of anticancer activity in vitro. This is evident by the concentration-dependent manner reduction in the final number of cancer cells as a consequence to treatment. On the other hand, despite its possible toxicity, E. jambolana is frequently used orally as a medication in many conditions by traditional medicine.
Figure 1: Percentage of inhibition of MCF-7 cells at different doses of glaucoside

Click here to view


Acknowledgment

This work has been supported by TNSCST grant (No. MS-24).

Financial Support and Sponsorship

Nil.

Conflicts of Interest

There are no conflicts of interest.

 
 » References Top

1.
Ponder BA. Cancer genetics. Nature 2001;411:336-41.  Back to cited text no. 1
    
2.
Cragg GM. Paclitaxel (Taxol): A success story with valuable lessons for natural product drug discovery and development. Med Res Rev 1998;18:315-31.  Back to cited text no. 2
    
3.
Pezzuto JM. Plant-derived anticancer agents. Biochem Pharmacol 1997;53:121-33.  Back to cited text no. 3
    
4.
Schwartsmann G. Marine organisms and other novel natural sources of new cancer drugs. Ann Oncol 2000;11 Suppl 3:235-43.  Back to cited text no. 4
    
5.
Lee KH. Novel antitumor agents from higher plants. Med Res Rev 1999;19:569-96.  Back to cited text no. 5
    
6.
Baliga MS. Anticancer, chemopreventive and radioprotective potential of black plum (Eugenia jambolana lam.). Asian Pac J Cancer Prev 2011;12:3-15.  Back to cited text no. 6
    
7.
Li L, Adams LS, Chen S, Killian C, Ahmed A, Seeram NP. Eugenia jambolana Lam. berry extract inhibits growth and induces apoptosis of human breast cancer but not non-tumorigenic breast cells. J Agric Food Chem 2009;57:826-31.  Back to cited text no. 7
    


    Figures

  [Figure 1]



 

Top
Print this article  Email this article
 

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow